Podcast
MSL Talk: Tom Caravela, Greg Auclair
Emotional Intelligence and why it is important for MSLs with Jessica Freund
Summary
In this episode, Jessica Freund from Biogen shares her journey into the pharmaceutical industry, highlighting her transition from Sanofi and her current role. The discussion delves into the significance of emotional intelligence for Medical Science Liaisons (MSLs), exploring its definition, teachability, and impact on career progression. Jessica provides insights on evaluating emotional intelligence during interviews and offers strategies for aspiring MSLs to navigate challenges and feedback. The conversation emphasizes the critical role of networking in career development. The episode concludes with Jessica's key advice and a call to action for listeners.
Today’s guest is Jessica Freund. Jessica is the Field Medical Director- Alzheimer’s Disease at Biogen. Our discussion is about emotional intelligence for MSLs and MSLs career development.
In this episode:
- Getting into the first job in the industry
- What is Emotional Intelligence
- Why is it important for MSLs to have emotional intelligence
- How does the application of emotional intelligence create opportunities
- Ways MSLs can strengthen their emotional intelligence
- What questions might be asked during interview that would help determine whether or not a person has a level of emotional intelligence
- Advice to those who really wanted to get into their first MSL role
Emotional Intelligence for MSLs, Medical Science Liaison career, Networking in pharmaceutical industry, Evaluating emotional intelligence, MSL interview strategies
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Greg Auclair
Podcast
MSL Talk: Tom Caravela, Dr. Tanya Johnson
An Unexpected Journey From Novice MSL to Global Medical Excellence Leader with Tonya Johnson
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO